DexCom, the world's pioneer in glucose biosensing, has unveiled its proprietary Generative AI platform, marking a significant innovation in the field of continuous glucose monitoring (CGM). Dexcom is the first CGM manufacturer to integrate GenAI technology, which analyzes individual health data to identify the direct link between lifestyle choices and glucose levels. The platform offers actionable insights that can help users improve their metabolic health. Stelo, Dexcom’s first FDA-cleared over-the-counter glucose biosensor, is the first product to utilize GenAI, delivering personalized weekly insights related to diet, exercise, and sleep within the Stelo app.
Built on Google Cloud’s Vertex AI and Gemini models, this new platform provides users with more personalized, data-driven recommendations. Jake Leach, Executive Vice President and COO of Dexcom, highlighted that this technology will enable users to make more informed, proactive decisions to manage their health. As Dexcom continues to enhance its product offerings, the GenAI platform is set to pave the way for future advancements in metabolic health management.
